title: Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
abstract: Using a case study of a 57-year-old man with relapsed/refractory precursor-B (pre-B) acute lymphoblastic leukemia (ALL), this review discusses treatment with immunoconjugates and autologous therapy in acute ALL. Three therapies--blinatumomab, inotuzumab, and CAR T cells--are considered here, each with advantages in specific clinical situations. These therapies represent some of the exciting advances that have been made in the treatment of ALL over the last several years.
authors.affiliation: Inpatient Leukemia Unit, Cleveland Clinic, 9500 Euclid Avenue, R35, Cleveland, OH 44195, USA. Electronic address: advania@ccf.org.
authors.forename: Anjali
authors.initials: A
authors.lastname: Advani
mesh_terms: D018033:Antibodies, Bispecific / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D002986:Clinical Trials as Topic; D005720:Gamma Rays / Q000627:therapeutic use*; D015870:Gene Expression; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D000080045:Inotuzumab Ozogamicin; D008297:Male; D008875:Middle Aged; D050506:Mutant Chimeric Proteins / Q000235:genetics / Q000378:metabolism; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology
chemical_list: D018033:Antibodies, Bispecific; D061067:Antibodies, Monoclonal, Humanized; D018796:Immunoconjugates; D050506:Mutant Chimeric Proteins; C510808:blinatumomab; D000080045:Inotuzumab Ozogamicin
keywords: ALL; Acute lymphoblastic leukemia; Antibody; BiTE; Blinatumomab; CAR; Chimeric antigen receptor; Inotuzumab